Related Experiment Video
Updated: Feb 5, 2026

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research
Published on: January 5, 2024
Interferon Gamma-Induced Protein (IP-10) as Potential Biomarker for Cancer-Related-Fatigue: Results from a 6-month
Emil Ter Veer1, Hetty Prinsen2, Mirjam A G Sprangers3
1a Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Department of Medical Oncology, Academic Medical Center , Meibergdreef 9 , Amsterdam , the Netherlands.
Abstract:
We examined if serum concentrations Interferon gamma-induced protein (IP-10) is a potential clinical biomarker for cancer-related-fatigue (CRF). Fatigue scores and IP-10 concentrations were measured from curatively treated fatigued cancer patients randomized to either cognitive behavioral therapy (CBT, n = 26) or waiting-list (WL, n = 13). No correlation was found between baseline IP-10 level and fatigue severity and no significant differences in IP-10 serum levels were observed between fatigued and matched non-fatigued patients (n = 22). Relative changes in IP-10 concentrations from baseline to six-month follow-up were not significantly different between the CBT and WL conditions. In this study, IP-10 showed low potential as clinical CRF biomarker.
Trial Registration:
This study is registered at ClinicalTrials.gov (NCT01096641).
Related Concept Videos
Fatigue
Controlled-Potential Coulometry: Electrolytic Methods
The chosen potential...
EPS and iPS Cells in Disease Research
Clinical Trials: Overview
Trial and Error and Algorithm
Clinical Trials
There are four phases in a clinical trial. A phase one...

